The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000569303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/03/2026
Date registered
Help: Date registered
5/05/2026
Date last updated
Help: Date last updated
5/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Evaluate the effectiveness of personalised Deep Brain Stimulation
Scientific title
Transforming epilepsy outcomes with personalised deep brain stimulation and extended intracranial evaluations in participants with drug-resistant epilepsy
Additional trial identifiers [1] 316479 0
NHMRC Ideas grant 2025 ID: 2048290
Universal Trial Number (UTN)
Trial acronym
TIDES
Related trial records

Health condition
Health condition(s) studied:
Drug Resistant Epilepsy 340603 0
Condition category
Condition code
Neurological 336799 336799 0 0
Epilepsy
Public Health 337533 337533 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants can undergo either or both interventions. (A) always occurs before (B), however, (A) is not required for enrolment in (B).

A) Extended Intracranial Evaluation – extended sampling and temporary stimulation of candidate Deep Brain Stimulation (DBS) targets during stereo-EEG (SEEG) evaluations. SEEG is a type of invasive intracranial evaluation involving the implantation of depth electrodes using a stereotactic surgical frame. Its aim is to more accurately define the brain regions involved in an individual's seizures, using recordings of electrical activity between and during seizures.
(A) Standard intracranial evaluations (e.g. SEEG) typically last 7–10 days, with our extended intracranial evaluation adding up to 2 additional days (7–12 days total). Temporary stimulation of candidate DBS targets will be performed by a study neurologist near the end of the admission. Stimulation trials will have parameters designed to mimic chronic DBS stimulation parameters and multiple parameter sets will be trialled of varying duration within safe charge density limits. The change in EEG-based biomarkers will be evaluated to assess the individual patient's response to each parameter set. The extended intracranial evaluation occurs once, to help treating clinicians decide on treatment for the individual's epilepsy, and follows standard neurosurgical procedure. As participants are admitted to hospital throughout the evaluation, adherence is maintained through continuous clinical monitoring.

B) Personalised DBS – DBS targets and stimulation parameters designed based on either results from (A) or standard-of-care evaluations.
(B) Participants undergoing personalised DBS will have their DBS system designed based on all available information – from standard-of-care (non-invasive) assessments through to our extended intracranial (invasive) evaluation. Stimulation target and parameters (e.g. amplitude, frequency) will be personalised to the individual's epilepsy, with parameters kept within safe charge density limits. DBS implantation will follow standard neurosurgical procedure. Adherence is supported by stimulation parameters being clinician-programmed and reviewed at scheduled follow-up appointments or ad-hoc if side effects occur.

All patients undergoing an intracranial evaluation will be offered an extended intracranial evaluation. All patients undergoing DBS will be offered personalised DBS. Standard of care will be given to those that opt-out, or those that do not meet inclusion criteria (e.g. <18yrs).
Intervention code [1] 333144 0
Treatment: Devices
Description of the comparator or control
Historical data of standard-of-care DBS. This typically involves bilateral stimulation of the anterior nucleus of the thalamus (ANT). Stimulation is delivered intermittently (1 minute on, 5 minutes off) at 145 Hz, 90 µs pulse width, and up to 5 V, cycling continuously, based on the SANTE trial protocol.. Parameters are generally uniform across patients and are not tailored to the individual's specific seizure network.
Intracranial evaluation is not a requirement for DBS and is only sometimes performed if the patient was considered for epilepsy surgery.
Historical data from The Alfred hospital (medical records ~Jan 2022-Apr 2026) and from the SANTE trial (published study ~Jan 2005-Dec 2010)
Control group
Historical

Outcomes
Primary outcome [1] 344321 0
Change to seizure frequency
Timepoint [1] 344321 0
6 months post intervention commencement
Primary outcome [2] 344322 0
Seizure severity
Timepoint [2] 344322 0
6 months post intervention commencement
Secondary outcome [1] 457465 0
Epilepsy specific quality of life
Timepoint [1] 457465 0
6 months post intervention commencement
Secondary outcome [2] 457466 0
Safety of thalamic Stereo-electroencephalography(SEEG)
Timepoint [2] 457466 0
6 months post intervention commencement
Secondary outcome [3] 457467 0
Safety of personalised DBS
Timepoint [3] 457467 0
2 months post intervention commencement
Secondary outcome [4] 460261 0
Depression
Timepoint [4] 460261 0
6 months post intervention commencement
Secondary outcome [5] 460700 0
General quality of life
Timepoint [5] 460700 0
6 months post intervention commencement
Secondary outcome [6] 460701 0
Epilepsy anxiety
Timepoint [6] 460701 0
6 months post intervention commencement
Secondary outcome [7] 460702 0
Seizure-related impact
Timepoint [7] 460702 0
6 months post intervention commencement

Eligibility
Key inclusion criteria
Participants must:
- Be aged 18 years or over.
- Have a diagnosis of drug-resistant epilepsy (according to ILAE criteria).
- Be able to read and speak English.
- Be medically and neurologically stable, aside from epilepsy, as judged by one of their clinicians or investigators.
- Be reasonably expected to maintain a seizure diary, alone or with the assistance of a competent individual.
- Be able to complete regular study visits and telephone or telehealth appointments in accordance with the study protocol.

Group A (Extended Intracranial Evaluation):
- Be under consideration for, have been recommended to have, or are planned to undergo intracranial EEG using one of the following modalities: (i) stereo-EEG, or (ii) subdural grids/strips and depth electrodes.

Group B (Personalised DBS):
- Be under consideration for, have been recommended to have, or are planned to undergo DBS or VNS for epilepsy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will not be enrolled if any of the following apply:
• Presence of unstable or terminal medical conditions
• Severe or unstable psychiatric condition, that in the judgement of the participant’s treating
neurologist/epileptologist, psychiatrist, or an investigator would preclude the ability to
participate in the trial or where participation would represent a risk for the participant
• Severe psychiatric condition that has not been assessed formally by a neuropsychiatrist
• Moderate to severe cognitive or intellectual impairment, that in the judgement of the
participant’s treating neurologist/epileptologist, psychologist, psychiatrist, or an investigator
would preclude the ability to participate in the trial
• Active suicidal plan/intent in the past 6 months, history of suicide attempt within 2 years, or
more than one lifetime suicide attempt
• Subjects unable to consent for themselves
• Presence of undue surgical risk, in the view of an investigator, including but not limited to
o Bleeding diathesis
o Inability to tolerate a general anaesthetic
o Participants for whom either subcortical sampling OR trial stimulation carries excessive
risk, in the opinion of the managing neurologist, neurosurgeon, or investigator
• Recent scalp infection of skin breakdown within the previous 6 weeks
• Recent surgical procedure within the previous 6 weeks that would constitute an
unacceptably high risk of infection

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
We will compare the effect of Extended Intracranial Evaluation + Personalised DBS, to Standard intracranial evaluation + Personalised DBS, and Historical data of standard-of-care DBS collected from hospital records.
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29108 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 45411 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 321090 0
Hospital
Name [1] 321090 0
The Alfred Research Trusts
Country [1] 321090 0
Australia
Funding source category [2] 321506 0
Government body
Name [2] 321506 0
NHMRC
Country [2] 321506 0
Australia
Primary sponsor type
Hospital
Name
The Alfred
Address
Country
Australia
Secondary sponsor category [1] 323797 0
None
Name [1] 323797 0
Address [1] 323797 0
Country [1] 323797 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319625 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319625 0
Ethics committee country [1] 319625 0
Australia
Date submitted for ethics approval [1] 319625 0
24/07/2025
Approval date [1] 319625 0
16/09/2025
Ethics approval number [1] 319625 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147902 0
Dr Hugh Simpson
Address 147902 0
The Alfred Centre, 99 Commercial Rd, Melbourne VIC 3004
Country 147902 0
Australia
Phone 147902 0
+61 410591233
Fax 147902 0
Email 147902 0
Contact person for public queries
Name 147903 0
Hugh Simpson
Address 147903 0
The Alfred Centre, 99 Commercial Rd, Melbourne VIC 3004
Country 147903 0
Australia
Phone 147903 0
+61 410591233
Fax 147903 0
Email 147903 0
Contact person for scientific queries
Name 147904 0
Hugh Simpson
Address 147904 0
The Alfred Centre, 99 Commercial Rd, Melbourne VIC 3004
Country 147904 0
Australia
Phone 147904 0
+61 410591233
Fax 147904 0
Email 147904 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.